Kivu Bioscience
Biotechnology
$92Mlatest round · Series A · Oct 2024 · 2 yr ago
3backers · BioGeneration Ventures, HealthCap
1-10team · employees, estimated range
40stories in the press
Overview
At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
Funding and backers
Total raised
$92M
1 round on record
Latest round
$92M
Series A · Oct 2024 · 2 yr ago
Team
1-10
employees, estimated range
Backers
3
BioGeneration Ventures, HealthCap
The money's age
Due for its next round
24 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 14
New executive Kivu Bioscience Appoints Mohit Trikha, Ph.D., as Chief Executive Officer · kivubioscience.com
Jan 26
Board appointment Kivu Bioscience Appoints Julie Hambleton, M.D., to its Board of Directors · businesswire.com
Oct 28, 2024
Raised a round Series A $92M · led by Novo Holdings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Oct 2024 | $92M | Novo Holdings lead | businesswire.com |
Backed byfrom the funds' portfolios and accelerator catalogs
HealthCap 
M Ventures Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Entia is making life better for people receiving cancer treatment.
Cairn Therapeutics: Targeting the Cancer, just the cancer. Making cancer treatment simpler and safer with CT-262.
Pioneering the first oral drug for FSHD and advancing cancer treatment solutions.
KAHR Bio: Pioneering Immunotherapeutics for Advanced Cancer Treatment.
Meet the Grannus leadership team—biotech veterans and oncology innovators united by a mission to deliver smarter, safer, and more effective…
Explore cutting-edge AI solutions for cancer treatment, diagnosis, and research. Discover how clinical labs leverage artificial…
Financials
Total raised
$92M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2024 | $92M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Kivu Bioscience CEO Mohit Trikha on
Kivu Bioscience CEO Mohit Trikha joins Ashley Mastronardi on NYSE Floor Talk
Read more
Report
BIO 2026: Kivu Bioscience exited stealth late last year to develop "kinder and gentler" antibody-drug conjugates with a lower antibody to payload ratio to improve precision and tolerability
CEO Mohit Trikha describes the idea behind this approach, which in many ways is the opposite of what many ADC developers have been working on. The lead programs target PTK7 and CEACAM5.
Read more
Report
Can ADCs be kinder and gentler? Join BioSpace at BIO to find out
While existing antibody-drug conjugates have been incredible advancements in cancer care, patients are ready for a better experience. At the BIO International Convention in San Diego on Thursday, BioSpace will lead a discussion on the next generation of A
Read more
Report
Facing pressure from China, BioSpace's NextGen biotech leaders say: 'Bring it on'
From Chinese innovation to AI, biotech CEOs are being hit with challenges at a breakneck pace. Three leaders from BioSpace's NextGen Class of 2026 told us about the issues keeping them up at night.
Read more
Report
Max Klement, PhD
Dr. Max Klement is a Principal at Novo Holdings who has more than 10 years of experience working in biotechnology and life science venture investments. Most recently, he was Principal at BioGeneration Ventures, a European life science venture capital firm
Read more
Report
Mohit Trikha, PhD
Dr. Mohit (Mo) Trikha is the CEO of Kivu Bioscience. He brings over 25 years of drug development expertise in oncology. He has been instrumental in advancing more than 40 programs from target identification to clinical trials in oncology. Previously, Mo w
Read more
Report
Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting 2026
- Clinical-stage PTK7 ADC KIVU-107 shows strong preclinical anti-tumor activity, favorable pharmacokinetics and improved tolerability - Next-generation CEACAM5 ADC KIVU-305 demonstrates potent preclinical activity and enhanced stability across colorectal
Read more
Report
Kivu Bioscience Appoints Mohit Trikha, Ph.D., as Chief Executive Officer
Proven oncology leader to advance next-generation ADC pipeline and drive clinical milestones SAN MATEO, CA - Kivu Bioscience, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers,
Read more
Report
Kivu Bioscience Appoints Brunilda Shtylla as Chief Business Officer
Seasoned biopharma executive brings more than 25 years of business development and strategic partnership experience to support Kivu's next phase of growth SAN MATEO, Calif.--(BUSINESS WIRE)--Kivu Bioscience, a clinical-stage biotechnology company developi
Read more
Report
Brunilda Shtylla
Brunilda Shtylla is Chief Business Officer of Kivu Bioscience, where she leads corporate strategy, business development, and partnership initiatives as the company advances its antibody-drug conjugate (ADC) pipeline through clinical development and expand
Read more
Report
Show more news